Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927198 · ClinicalTrials.gov registry record · Phase 2
RDEA3170 Monotherapy in Subjects With Gout
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT01927198: Completed Phase 2 study, sponsored by Ardea Biosciences.
NCT01927198 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 172 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01927198, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
Primary Outcome
Percent change from baseline in serum urate levels at Week 12.
Interventions
- DRUG Placebo
- DRUG RDEA3170 5 mg
- DRUG RDEA3170 10 mg
- DRUG RDEA3170 12.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT01927198 record still lists
NCT01927198 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01927198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01927198 about?
NCT01927198 is a clinical study titled "RDEA3170 Monotherapy in Subjects With Gout". This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
What is the current status of trial NCT01927198?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2013-08. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01927198?
The interventions under investigation include: Placebo (DRUG), RDEA3170 5 mg (DRUG), RDEA3170 10 mg (DRUG), RDEA3170 12.5 mg (DRUG).
Who is sponsoring clinical trial NCT01927198?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01927198's enrollment target sits among peer trials
172 397th of 2000 higher than 1,603 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia